% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sturm:125372,
      author       = {D. Sturm$^*$ and S. Pfister$^*$ and D. Jones$^*$},
      title        = {{P}ediatric {G}liomas: {C}urrent {C}oncepts on {D}iagnosis,
                      {B}iology, and {C}linical {M}anagement.},
      journal      = {Journal of clinical oncology},
      volume       = {35},
      number       = {21},
      issn         = {1527-7755},
      address      = {Alexandria, Va.},
      publisher    = {American Society of Clinical Oncology},
      reportid     = {DKFZ-2017-01505},
      pages        = {2370 - 2377},
      year         = {2017},
      abstract     = {Gliomas are the most common CNS tumors in children and
                      adolescents, and they show an extremely broad range of
                      clinical behavior. The majority of pediatric gliomas present
                      as benign, slow-growing lesions classified as grade I or II
                      by the WHO classification of CNS tumors. These pediatric
                      low-grade gliomas (LGGs) are fundamentally different from
                      IDH-mutant LGGs occurring in adults, because they rarely
                      undergo malignant transformation and show excellent overall
                      survival under current treatment strategies. However, a
                      significant fraction of gliomas develop over a short period
                      of time and progress rapidly and are therefore classified as
                      WHO grade III or IV high-grade gliomas (HGGs). Despite all
                      therapeutic efforts, they remain largely incurable, with the
                      most aggressive forms being lethal within months. Thus, the
                      intentions of neurosurgeons, pediatric oncologists, and
                      radiotherapists to improve care for pediatric patients with
                      glioma range from increasing quality of life and preventing
                      long-term sequelae in what is often a chronic, but rarely
                      life-threatening disease (LGG), to uncovering effective
                      treatment options to prolong patient survival in an almost
                      universally fatal setting (HGG). The last decade has seen
                      unprecedented progress in understanding the molecular
                      biology underlying pediatric gliomas, fueling hopes to
                      achieve both goals. Large-scale collaborative studies around
                      the globe have cataloged genomic and epigenomic alterations
                      in gliomas across ages, grades, and histologies. These
                      studies have revealed biologic subgroups characterized by
                      distinct molecular, pathologic, and clinical features, with
                      clear relevance for patient management. In this review, we
                      summarize hallmark discoveries that have expanded our
                      knowledge in pediatric LGGs and HGGs, explain their role in
                      tumor biology, and convey our current concepts on how these
                      findings may be translated into novel therapeutic
                      approaches.},
      subtyp        = {Review Article},
      cin          = {B062 / L101},
      ddc          = {050},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)L101-20160331},
      pnm          = {312 - Functional and structural genomics (POF3-312)},
      pid          = {G:(DE-HGF)POF3-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28640698},
      doi          = {10.1200/JCO.2017.73.0242},
      url          = {https://inrepo02.dkfz.de/record/125372},
}